Soon-Shiong's NantWorks deepens its immuno-oncology ties with Sorrento

NantHealth founder Patrick Soon-Shiong

Billionaire biotech entrepreneur Patrick Soon-Shiong is expanding his company's relationship with Sorrento Therapeutics ($SRNE), promising $110 million in cash and equity in exchange for the rights to some cancer-fighting immunotherapies. Under the alliance, an arm of Soon-Shiong's NantWorks empire is teaming up with Sorrento to develop new treatments that pair the biotech's antibody discovery platform with its own genomics-based R&D. The subsidiary, NantCell, is paying out $10 million in cash and $100 million in equity for the rights to collaborate, and Sorrento is in line for a share of future profits from any resulting product. The deal comes on the heels of a December pact between the two companies that resulted in NantiBody, a joint venture also focused on cancer immunotherapy. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.